Research Topics
| Vittoria GebbiaSummaryCountry: Italy Publications
| Collaborators
|
Detail Information
Publications
Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia MeridionaleVittorio Gebbia
La Maddalena Clinic for Cancer, Department of Experimental Oncology and Clinical Applications, University of Palermo, Italy
Am J Clin Oncol 33:461-4. 2010....
Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agentsVittorio Gebbia
UO Oncologia Medica, La Maddalena, Universita di Palermo, Palermo, Italy
Expert Opin Drug Saf 11:S49-59. 2012..EXPERT OPINION: Adherence and persistence to new oral biologic agents, which are linked to several side effects and whose use is constantly widening, should represent a main endpoint of clinical research in the nearest future...
Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinomaVittorio Gebbia
Medical Oncology Unit La Maddalena Cancer Clinic, via San Lorenzo Colli n 312d, 90100 Palermo, Italy
Anticancer Res 32:529-36. 2012..Its mechanism of action probably involves antiangiogenetic effect rather than a classical antiproliferative effect like standard maximally tolerated dose-based regimens...
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trialSandro Pignata
Medical Oncology B, National Cancer Institute, Naples, Italy
BMC Cancer 6:202. 2006..Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned...
Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II studyVittorio Gebbia
Department of Experimental Oncology, University of Palermo, Italy
Anticancer Drugs 14:359-64. 2003..This level of activity overlaps with the 95% CL of the activity of cisplatin alone; however, it does encourage future trials of the combination...
Systemic chemotherapy in elderly patients with locally advanced and/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and role of recombinant human erythropoietinVittorio Gebbia
Medical Oncology Researcher, Chair of Hematology, University of Palermo, Via Alessandro Paternostro n 48, 9013 Palermo, Italy
Crit Rev Oncol Hematol 48:S49-55. 2003..rhEpo also caused a positive effect on quality of life (QoL) parameters...
Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trialsV Gebbia
Department of Experimental Oncology and Clinical Applications, University of Palermo, Medical Oncology Unit, La Maddalena Clinic for Cancer, Palermo, Italy
Ann Oncol 16:iv123-131. 2005
Oral versus intravenous vinorelbine: clinical safety profileVittorio Gebbia
Department of Experimental Oncology and Clinical Applications, University of Palermo, Palermo, Italy
Expert Opin Drug Saf 4:915-28. 2005....
Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experienceVittorio Gebbia
Department of Experimental Oncology and Clinical Applications, University of Palermo, and Medical Oncology Unit, Ospedale San Giovanni di Dio, Napoli, Italy
Clin Colorectal Cancer 5:422-8. 2006....
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomasV Gebbia
Medical Oncology Units of the Department of Experimental Oncology and Clinical Applications, University of Palermo, Italy
Ann Oncol 17:vii60-5. 2006..The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer...
Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM)Vittorio Gebbia
Department of Experimental Oncology and Clinical Application, University of Palermo, Italy
Anticancer Res 26:3143-50. 2006....
Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practiceV Gebbia
Department of Experimental Oncology and Clinical Applications, University of Palermo, La Maddalena Clinic for Cancer, Palermo, Italy
Ann Oncol 18:vi124-7. 2007..In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support...
Cetuximab in squamous cell head and neck carcinomasV Gebbia
Medical Oncology Unit, La Maddalena Hospital, Palermo, Italy
Ann Oncol 18:vi5-7. 2007..In this paper, we report a review of the major studies dealing with the use of cetuximab in advanced head and neck cancer...
Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale)Vittorio Gebbia
Department of Experimental Oncology and Clinical Applications, University of Palermo, Italy
Lung Cancer 61:369-77. 2008..The primary endpoints were overall survival (OS) and analysis of toxicity, while secondary endpoints included response rates, time-to-progression (TTP) and quality of life (QoL)...
Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?Vittorio Gebbia
Medical Oncology University of Palermo, Department of Experimental Oncology and Clinical Applications, Palermo, Italy
Expert Opin Pharmacother 9:1321-37. 2008..A growing percentage of patients affected by advanced non-small cell lung cancer who progressed after first-line chemotherapy still have a good performance status and require second-line treatment...
First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia MeridionaleVittorio Gebbia
Medical Oncology Unit, University of Palermo, La Maddalena Clinic for Cancer, Palermo, Italy
Lung Cancer 69:218-24. 2010..The impact of these regimens on patients' QoL as well as symptoms control and type and grading chemo-related side-effects has been compared prospectically...
Evolution of therapy decision-making process for advanced non-small cell lung cancerVittorio Gebbia
Department of Experimental Oncology and Medical Applications DOSAC, University of Palermo, and Medical Oncology Division, La Maddalena Clinic for Cancer, Palermo, Italy
Oncology 77:97-102. 2009..The results of new biologic agents are also reported as are the promising data on pharmacogenomic-guided treatment...
Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinomaVittorio Gebbia
Institute of Clinical Medicine, University of Palermo, Italy
Breast Cancer Res Treat 77:99-108. 2003..A phase I-II trial was carried out to test the feasibility and the activity of a new bimonthly schedule of DCT...
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospeVittorio Gebbia
Institute of Internal Medicine, University of Palermo, Via Alessandro Paternostro n 48, 90133 Palermo, Italy
Lung Cancer 39:179-89. 2003..The primary endpoint was survival parameters, while secondary endpoints included analysis of response rates and toxicity...
Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervixVittoria Gebbia
Institute of Internal Medicine, University of Palermo, Palermo, Italy
Oncology 63:31-7. 2002..The main aims of the study included analysis of objective response rates, toxicity, and time to progression...
Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigationVittorio Gebbia
Institute of Internal Medicine, University of Palermo, Palermo, Italy
Oncology 63:23-30. 2002..Moreover, the combination of VNR and pegylated liposomal doxorubicin is active against metastatic breast carcinoma and is associated with a good toxicity profile. Further studies with this combination regimen are warranted...
Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized studyVittorio Gebbia
Istituto Clinica Medica, University of Palermo, Palermo, Italy
Lung Cancer 37:179-87. 2002..The main endpoits were analysis of objective response rates, toxicity, time to progression, and overall survival...
Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 casesV Gebbia
Service of Chemotherapy, Institute of Pharmacology, Palermo, Italy
Br J Cancer 68:191-4. 1993..The employed regimens have been generally well tolerated. These data confirm that NPC is a neoplasm highly responsive to chemotherapy. However, duration of objective response and survival are still largely unsatisfactory...
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized studyG Cocconi
Medical Oncology Institution of Parma, Parma, Italy
Melanoma Res 13:73-9. 2003....
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinomaS Palmeri
Section of Clinical Oncology, University of Palermo, Italy
J Chemother 3:170-5. 1991..The recommended doses for a phase II study are cisplatin 20 mg/m2/week, 5-fluorouracil 400 mg/m2/week, and citrovorum factor 500 mg/m2/week...
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)F De Vita
Division of Medical Oncology, Second University, Napoli, Italy
Ann Oncol 18:1354-8. 2007..This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients...
Anaemia in cancer: pathophysiology and treatmentS Mercadante
La Maddalena Clinic for Cancer, Palermo, Italy
Cancer Treat Rev 26:303-11. 2000..These measures are unlikely to have an effect in irreversible and progressive bleeding states...
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective studyS Mercadante
Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Palermo, Italy
J Clin Oncol 19:2898-904. 2001..To evaluate the clinical benefits of switching from morphine to oral methadone in patients who experience poor analgesia or adverse effects from morphine...
Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimenV Gebbia
Istituto Clinica Medica, Policlinico, University of Palermo, Italy
Ann Oncol 12:767-72. 2001..In our opinion the CDDP plus VNR regimen is good enough to be compared to the anthracycline-based regimens and may represent the basis for future development of newer active polychemotherapeutic schedules...
A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapyV Gebbia
Service and Chair of Chemotherapy, Policlinico, University of Palermo, Italy
Anticancer Res 14:731-4. 1994..Similar results were achieved for fungal infections. Tolerance to thymopentin was excellent, while less than 9% of patients on G-CSF treatment complained of mild nausea and generalized bone pain...
Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomachV Gebbia
Chair and Service of Chemotherapy, Institute of Pharmacology, Palermo, Italy
J Chemother 6:147-51. 1994..Despite the use of epidoxorubicin 75 mg/m2, the 26.4% (95% confidence limits 16-36%) objective response rate is not satisfactory. Evaluation of more aggressive protocols is strongly recommended within the limits of controlled trials...
A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinomaA Callari
Service of Chemotherapy, Oncological Hospital M. Ascoli, Palermo, Italy
Acta Oncol 33:925-9. 1994..Results of the present and similar studies may, however, be useful for planning of neoadjuvant or adjuvant trials with curative intent...
Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?V Gebbia
Department of Experimental Oncology and Clinical Applications University of Palermo, and La Maddalena Clinic for Cancer, Palermo, Italy
Ann Oncol 17:ii83-87. 2006
5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization studyS Palmeri
Section of Clinical Oncology, University of Palermo, Italy
J Chemother 2:327-30. 1990..The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU. At this dose level all patients required dose reduction due to fatigue, fever, myalgia and severe reduction of performance status...
Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II studyC Gridelli
Oncologia Medica B, Istituto Nazionale Tumori, Napoli, Italy
Anticancer Res 21:4179-83. 2001..c. days 6 to 15) administered every 3 weeks for 4 cycles and subsequent chest irradiation (50 Gy) + daily carboplatin (25 mg/m2) in the first-line treatment of adults affected by limited small cell lung cancer (SCLC)...
A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinomaV Gebbia
Service of Chemotherapy, University of Palermo, Italy
J Chemother 5:186-90. 1993..Further studies are required to establish if the increase in dose-intensity allowed by G-CSF treatment may positively influence the outcome of cancer patients...
Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancerV Gebbia
Service of Chemotherapy, University of Palermo, Italy
Br J Cancer 73:1576-80. 1996..Data on body weight suggest that after 2 weeks' therapy MA could be stopped or its dosage tailored to patients' needs since the majority of patients respond after only 15 days of MA...
Mental nerve invasion by basal cell carcinoma of the chin: a case reportC Di Gregorio
Institute of Pathology, Palermo, Italy
Anticancer Res 18:4723-6. 1998..This report stresses the importance of a correct follow-up and an accurate clinical staging in order to identifying clinical signs highly suspicious for neoplastic perineural infiltration...
The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitroV Gebbia
Section of Oncology, University of Palermo, Italy
Tumori 78:167-71. 1992..In conclusion, these data suggest that bryostatin-1 is a potent antileukemic agent in vitro that may be potentially useful for clinical studies...
